GSK board conflict of interest
Executive Summary
Case Western Reserve University School of Medicine Dean Ralph Horwitz will not join GlaxoSmithKline's board as a non-executive director due to a potential conflict of interest concerning a decongestant component of a withdrawn SmithKline Beecham product. Horwitz was an investigator in a study linking phenylpropanolamine to hemorrhagic stroke. Over-the-counter medicines containing PPA were withdrawn from the market in 2000, prompting lawsuits against GSK and other drug makers (1"The Pink Sheet" Nov. 13, 2005, p. 25)...
You may also be interested in...
Knoll Meridia Discount Program Uses Advance PCS Pharmacy Card
Advance PCS will manage Knoll Pharmaceutical's discount program for its weight-loss product Meridia.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.